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Abstract
The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understanding of the tumor microenvironment (TME) and
tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune
response. The approval of new immune and targeted therapies has further improved outcomes for patients with
advanced melanoma and other combination modalities are also being explored such as chemotherapy, radiotherapy,
electrochemotherapy and surgery. In addition, different strategies of drugs administration including sequential or
combination treatment are being tested. Approaches to overcome resistance and to potentiate the immune response
are being developed. Increasing evidence emerges that tissue and blood-based biomarkers can predict the response
to a therapy. The latest findings in melanoma research, including insights into the tumor microenvironment and new
biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination
strategies and the role of neoadjuvant and adjuvant therapy, were the focus of discussions at the Melanoma Bridge
meeting (5–7 December, 2019, Naples, Italy), which are summarized in this report.
Keywords: Melanoma, Immunotherapy, Anti-PD-1, Anti-CTLA-4, Target therapy, Biomarkers, CAR-T, BRAF inhibitor,
MEK inhibitor, Adjuvant, Neoadjuvant, Combination strategies
Introduction
The melanoma treatment landscape changed in 2011
with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor
and of the first BRAF-targeted monoclonal antibody,
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both of which significantly improved overall survival
(OS). Since then, improved understanding of the tumor
microenvironment (TME) and tumor immune-evasion
mechanisms has resulted in different approaches to targeting and harnessing the host immune response. The
approval of new immune and targeted therapies has
further improved outcomes for patients with advanced
melanoma using various approaches with distinct modes
of action including single or combination of immunotherapy agents, and other combination modalities are
also being explored such as chemotherapy, radiotherapy,

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeco
mmons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Ascierto et al. J Transl Med

(2020) 18:346

electrochemotherapy and surgery. In addition, different
strategies of drugs administration including sequential
or combination treatment may potentially be associated
with clinically relevant improvement of outcome.
However, better understanding of resistance mechanisms and reasons why some patients do not respond,
or relapse is needed. Treatment strategies in the clinical management of melanoma are evolving in order to
address these challenges. Approaches to overcome resistance and to potentiate the immune response are being
developed. Increasing evidence emerges that tissue and
blood-based biomarkers can predict the response to a
therapy. Predictive biomarkers can be considered for
patients stratification or selection of patients who will
most likely achieve favorable clinical outcome.
The latest findings in melanoma research, including insights into the tumor microenvironment and new
biomarkers, improved understanding of tumor immune
response and resistance, novel approaches for combination strategies and the role of neoadjuvant and adjuvant
therapy, were the focus of discussions at the Melanoma
Bridge meeting (5–7 December, 2019, Naples, Italy),
which are summarized in this report.

Melanoma Bridge opening session
Biomarkers for immunotherapy of cancer

The progress in fully realizing the potential of biomarkerdriven assignment for anticancer approaches in immune
oncology (IO) requires the development and implementation of novel clinical-grade biomarkers able to guide
the selection of a single therapy agent or combination
of drugs with complementary mechanisms of action
targeting multiple mechanisms of response as well as of
immune escape.
Biomarkers for immunotherapy require comprehensive approaches that encompass the complexity of the
immune system and tumor biology which cannot be
addressed using a single analyte biomarker. Therefore,
investigation of the biology and genomics of both the
tumor and the host immune system is critical to recognize potential biomarkers. The availability of novel platforms and technologies should facilitate the integration
of the molecular features of the tumor and the host factors for the development of multiplex profiles to guide
personalized treatment in the future. However, before
a candidate biomarker and/or new technology can be
used in a clinical setting, rigorous steps to demonstrate
the analytical and clinical validity of the biomarkers are
required. The challenges to overcome include, the inherent complexity of the assays and independent protocols
that result in high data variability and poor reproducibility across sites and studies as well as the requirements for
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highly specialized bioinformatics expertise for data interpretation and integration of multi-omics data.
In recognition of these challenges, in 2017 the US
National Cancer Institute (NCI) at National Institutes
of Health (NIH) has established the Cancer Immune
Monitoring and Analysis Centers-Cancer Immunologic
Data Commons (CIMAC-CIDC) Network. The Network
is composed of four laboratories (CIMACs) and a biomarker data storage/access platform (CIDC), to enable
systematic analysis and integration of biomarkers associated immunotherapy clinical trials. The overall goals for
the CIMAC-CIDC Network are to conduct correlative
studies focusing on biomarkers of response and resistance in NCI-supported early-phase immunotherapy trials by offering a wide range of validated analyses using
state-of-the-art methods. The network will also facilitate
innovative research for new biomarkers, capitalizing on
recent advances in immune profiling platforms and technologies, provide centralized bioinformatics resources
for data collection and integration across trials, and
establish a biomarker database.
Biomarker assays are categorized at tier one, which are
broadly recommended for most trials and have harmonized SOPs available across the Network sites including,
multiplex immunohistochemistry (mIHC) and immunofluorescence (mIF) panels, mass cytometry (CyTOF),
RNA sequencing, whole exome sequencing and T cell
receptor (TCR) analysis. Tier two and three assays constitute experimental approaches for which usage depends
on the specific trial. In 2018, Partnership for Accelerating Cancer Therapies (PACT) was launched as a public–
private partnership with 12 leading biopharmaceutical
companies, the NIH, the Food and Drug Administration
(FDA), and the Foundation for NIH (FNIH). PACT supports comprehensive immunoprofiling using CIMACs
validated assays for IO biomarkers for response to treatment in the industry sponsored immunotherapy trials.
Harmonization of laboratory specific protocols with
SOPs and assay performance benchmarks which is the
goal of the CIMACs-CIDC Network is necessary to
overcome variability of methods and data collection in
both academic and industrial laboratories and enable
objective interpretation and comparison across different studies and multiple sites. Assay harmonization is
an essential component of developing a biomarker database for secondary analyses to accelerate optimization
of immunotherapies and the potential success of new
immunotherapy agents and combinations.

Session—melanoma as a model system
Harnessing the gut microbiome to optimize cancer therapy

The activity of the commensal microbiota significantly
impacts human health and has been linked to the
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development of many diseases, including cancer. Recent
study demonstrated that the composition of the gut
microbiome can influence the effect of cancer therapy
by modulating the antitumor immune response efficacy.
Several recent studies have established that the composition of the gut microbiome modulates the efficacy of antiPD-1 therapy [1–3]. Microbiota taxonomic identification
in cancer patients may be affected by geography, disease
and sequencing technology. Moving forward, there is a
need for a deeper understanding of the underlying biological mechanisms that link specific bacterial strains to
host immunity because microbial species associated with
anti-PD-1 response in different patients are not always
the same across different cohorts. Integrating microbiome effects with other tumor and host factors regulating
immunotherapy responsiveness could facilitate optimization of therapeutic outcomes.
Even though there is increasing evidence that the
microbiome has a role in influencing the response to
therapy, it is not yet known what constitutes a favorable
microbiome composition or whether gut microbiota can
be altered to improve therapeutic response. However,
it opens the exciting possibility to improve efficacy by
manipulating the gut flora and various strategies to target
the microbiome have been suggested, including antibiotics, probiotics, prebiotics, diet, oral bacterial formulations and fecal microbial transplant (FMT).
FMT approach delivers a fecal microbiota transplant
(FMT) and the promise to transfer its beneficial effect.
For example, fecal samples could be prepared from antiPD-1 responders that show a favorable composition of
commensal bacteria, then transplanted endoscopically
or prepared for oral delivery into patients who are antiPD-1-resistant and show an unfavorable composition of
gut microbes. FMT is being assessed in ongoing trials in
patients with melanoma who are refractory to anti-PD-1
treatment. In an ongoing study at the University of Pittsburgh, patients who are non-responders to pembrolizumab at 12 weeks are receiving FMT from a responder
patient, with promising preliminary results. An approach
using “commensal community” approach is a community of bacterial strains from healthy human donor feces
that induces interferon (IFN)-γ-producing CD8 T cells
improved the therapeutic efficacy of immune checkpoint
inhibitors in syngeneic tumor models [4] and other trials
using different consortia are ongoing.
Alternatively, beneficial or immune-potentiating bacteria could be prepared as a probiotics and provided as an
immunotherapy adjuvant. Another approach is dietary
intervention. Habitual diet is a key determinant of the gut
microbiota, and the microbiome composition can be rapidly changed by switching from a high-fat, low-fiber diet
to a low-fat, high-fiber diet or vice versa.
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All of these approaches lack the precision to modulate
very specific bacterial populations and may have variable
effects depending on the starting state of the commensal
community. This variability offers research potential and
requires exploiting the host–microbiome interdependency to consider for personalized therapy. Future goals
are the discovery of reliable microbiome-related biomarkers for prediction of response and stratification of
patients as well as the identification of favorable microbiota for fecal transfer from responder patients or healthy
donors. Identification of communities of commensal bacteria that deliver more potent therapy may be important
for integrating microbiome effects with other tumor and
host factors regulating immunotherapy responsiveness
could facilitate optimization of therapeutic outcomes.
The unsolved issues in treatment of melanoma
in the adjuvant setting

Since 2015, several adjuvant treatments for resected stage
III–IV melanoma have been approved. Active adjuvant
phase III placebo-controlled trials in melanoma include
the CheckMate-76 study of nivolumab and the KEYNOTE-716 study of pembrolizumab, with both studies
enrolling patients with resected stage IIb/c disease. These
patients have similar survival rates as patients with stage
IIIa/b and may benefit from adjuvant therapy.
Implementation of the American Joint Committee on
Cancer (AJCC) 8th edition staging manual may disrupt
analyses of active adjuvant clinical trials. It has been
noted that it is difficult to extrapolate and compare the
data from one trial to another, complicating interpretation of current and future trial results in resected stage
III melanoma [5]. In analysis of the NYU Interdisciplinary Melanoma Program Database which staged all
patients according to AJCC-7 and AJCC-8 guidelines,
there was significant improvement in prognostic value
for stage III with addition of the IIID sub-stage. However,
stage IIC continues to have worse prognosis than IIIA in
the revised system.
Approval of adjuvant immunotherapies has led to their
inclusion as standard of care for patients with high-risk
resected stage III–IV disease. Stage III comprises ~ 23%
of new cases each year with ~ 21,500 new cases in the
USA each year. Clinical trials have very strict inclusion
criteria, but these do not apply to patients treated with
standard of care in clinical practice so there may be
higher potential for toxicity in this patient cohort. Stage
IIB/C patients represent around 10% of new cases, and
the challenge is to balance clinical benefit with the risk
of toxicity. Only one in four stage III patients benefit
from adjuvant therapy [6, 7] and only one in eight stage II
patients are expected to derive such benefit.
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Although, treatment with combined ipilimumab and
nivolumab yielded high response rates (RECIST ORR
73%, pCR 45%) substantial treatment-related adverse
events (trAEs) (73% grade 3 trAEs) was observed in
this cohort. Whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%)
and low toxicity (8% grade 3 trAEs). Immune correlates
of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a
more clonal and diverse T cell infiltrate in responders to
nivolumab monotherapy [8].
Treatment-related factors associated with response
and toxicity are well characterized, but host factors also
need to be considered as adjuvant therapy becomes
more widely available. These include the tumor molecular features including T cell infiltrate, mutational load,
gut microbiome, germline genetics, proteomic biomarkers and possibly ethnicity. Composition and abundance
of the gut microbiome was shown to be associated with
immune checkpoint inhibitor response [9]. Two autoimmune germline variants as potential biomarkers of antiCTLA4 or anti-PD1 immune checkpoint inhibitors (ICI)
efficacy in melanoma were identified and suggests that
underlying genetic susceptibility to autoimmunity may
play an important role during ICI treatments. rs1893217
in PTPN2, involved in cytokine signaling, has been associated with colitis, celiac disease, inflammatory bowel,
rheumatoid arthritis and type 1 diabetes. Similarly,
rs17388568 was mapped to important immune-related
genes (IL-2, IL-21 and ADAD1) and associated with
allergy, colitis and type 1 diabetes [10]. Ongoing research
focused on predicting response and toxicity emphasizes
the need for additional studies to optimize treatment regimens and to validate putative biomarkers that will allow
patient selection for adjuvant immunotherapy, an important consideration as the number of patients receiving it
as a standard of care increases.
Emerging targets in the tumor microenvironment
to improve radiotherapy and immunotherapy
combinations

Increasing the numbers and activation of a specific
dendritic cell (DC) subset, conventional type 1 DCs
(cDC1s), in tumors can potentially increase the responsiveness of cancer patients to immunotherapy. cDC1s
initiate de novo T cell responses after migrating to
tumor-draining lymph nodes, as well as recruiting
T cells, secreting cytokines e.g. IL-12, and presenting tumor antigens in the tumor microenvironment
(TME) (PMID: 30352680). Radiation therapy mediates
antineoplastic effects not only by cytotoxic and cytostatic mechanisms, but also by modulating both local
and systemic immunological function. However, the
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mechanisms by which radiation induces antitumor T
cells remain unclear. Radiation therapy activates a viral
defense response pathway, in which cytosolic DNA
stimulates secretion of IFN-β by cancer cells following
activation of the DNA sensor cGAS and its downstream
effector stimulator of interferon genes (STING). Repeat
irradiation at doses that induce optimal cytosolic DNA
accumulation amplifies IFN-β production, resulting in
recruitment and activation of cDC1s, also known as
Batf3-dependent DCs, which are essential for priming
of CD8+ T cells that mediate systemic tumor rejection (the abscopal effect). However, epigenetic downregulation of cGAs and/or STING in some tumors
may preclude the activation of IFN type I by radiation
therapy (REF: PMID: 29367762). We have recently
identified an alternative pathway for the recruitment
and activation of cDC1 to irradiated tumors. The balance between pro-inflammatory NAD+ and ATP and
immunosuppressive adenosine in the TME regulates
immune responses, with the accumulation of extracellular adenosine a strategy used by tumors to escape
immunosurveillance [11]. CD73 is an ecto-5-nucleotidase that is essential for the generation of extracellular
adenosine from 5-adenosine monophosphate (5-AMP).
CD73 is the final enzyme for both the canonical and
non-canonical adenosine generation pathways In the
canonical pathway CD39 (ecto-nucleoside triphosphate
diphosphohydrolase-1; ecto-NTPDase1) catalyzes the
phospho hydrolysis of ATP and ADP to AMP. In the
non-canonical pathway, CD38 catalyzes the conversion of NAD+ to ADPR and CD203a converts ADPR
to AMP (PMID: 27209048). Radiation-induced cell
death is associated with release of ATP and NAD+ in
the TME, but we found that radiation also induces the
upregulation of CD38, CD203a and CD73 on cancer
cells. Antibody-mediated blockade or genetic knockdown of CD73 restored the recruitment and activation of cDC1 to irradiated tumors that lacked cGAS
expression and were unable to produce IFNγ (PMID:
32047024). CD73 blockade led to increased infiltration
and activation of CD8+ T cells and decreased regulatory T cells (Treg) in the tumor, associated with complete tumor regression during dual CD73 and CTLA-4
blockade in combination with irradiation.
Thus, CD73 acts as immune checkpoint that precludes
radiation-induced anti-tumor T cell activation. High
levels of soluble CD73 at baseline have been associated
with poor OS and PFS in metastatic melanoma patients
treated with nivolumab [12]. Blocking CD73-dependent
adenosine-mediated immunosuppression may have the
potential to reinstate anti-tumor immunity and synergize
with radiotherapy and immune checkpoint blockade to
improve tumor control in patients.
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Immunotherapy‑induced anti‑cancer responses
to the spectrum of “Cancer Antigens” and immune
contraction

For over 30 years, immune responses against shared
cancer antigens have provided evidence of therapeutic
activity in preclinical and clinical studies. There is a coordinated B and T cell response to cancer and evidence that
IgG responses can correlate with CD8 T cell response.
Observations have indicated that circulating cytotoxic
T lymphocytes (CTLs) can recognize and eliminate lung
cancer cells presenting endogenous non-mutated peptides [13]. Specifically, they demonstrated that NSCLC
patients’ sera were found to have IgG antibodies to dozens of proteins from which peptides that were presented
on HLA by the NSCLC tumor cells originate. They show
that patients could mount a cytotoxic lymphocyte (CTL)
response to nonmutated peptides from the same proteins
that were the target of IgG responses, and that these CTL
could lyse an HLA-matched allogeneic NSCLC.
These and other data suggest patients have broad anticancer immunity against self-non-mutated epitopes
and that IgG antibodies identify targets of CD8 T cell
response. It is possible that once ‘re-activated’ with antigen and cytokine, T cells can kill cancer cells.
Correlation between increased CD8+ T cell IFN-γ
release and serum IgG binding was also demonstrated
by a study in which female BALB/c mice were vaccinated
with a combination of an autophagosome-enriched vaccine derived from 4T1 mammary carcinoma along with
poly-I:C adjuvant where serum was screened for IgG
binding to arrays of peptides containing known mutation sites in 4T1 [14]. Simultaneously, CD8+ T cell cultures were primed with peptides derived from these
antigens. These primed T cells were then stimulated to
measure recognition of the peptides or live 4T1 cells by
IFN-γ release. Vaccinated mice showed elevated antigen specific CD8+ T cell recognition of 4T1 tumor cells
and CD8 specific peptides. Antibodies had stronger
recognition of neoantigens peptides than autoantigens
counterpart peptides which differ by a single amino acid
substitution, suggesting a bias for the recognition of certain antigens prior to tumor exposure, which may be
due to the tolerance to autoantigens or prior exposure
to cross-reactive foreign antigens. There was a correlation between increased CD8+ T cell IFN-γ release and
serum IgG binding to individual peptide antigens. These
reports suggest that antibody immunosurveillance is
occurring in early in cancer patients and that IgG antibody responses can be used to identify proteins that
are targeted by T-cell responses. Potentially, the benefits of immune checkpoint blockade may be restricted
to tumors with pre-existing immune recognition, thus
evaluation of immune status may serve as a biomarker for
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personalization of immuno-therapy. Furthermore, lack of
pre-existing immune response should identify patients
for de novo boosting immune response including vaccination or combination with other agents that might
improve therapeutic efficacy. The DRibbles vaccine is
comprised of autophagosome vesicles that contains more
than 100 shared cancer antigens. The effect of vaccination with the first allogeneic human DRibbles vaccine,
DPV-001, on IgG responses to proteins overexpressed
by many/most cancers is being assessed with promising
results.
The role of melanoma derived exosome in modifying
the tumor microenvironment

Exosomes are members of the extracellular vesicle community including micro vesicles and oncosomes that
originate from multivesicular bodies and that contain
proteins, mRNA, microRNA and DNA and are enriched
in tetraspanins, i.e. proteins containing four transmembrane domains. Exosomes are cell-derived nano-meter
sized (40–100 nm) particles that have been established to
play an important role in cell-to-cell communication [15].
Tumor derived exosomes (TEX) have profound impact
on the immediate tumor microenvironment (TME) and
they can play a role at distant tissue sites to create a premetastatic niche conducive to metastasis and are referred
as the tumor “macroenvironment” (TMaE). TEX deliver
tolerogenic signals to immune cells, inhibiting immune
cell proliferation, inducing apoptosis of activated CD8+
T lymphocytes, interfering with monocyte differentiation and promoting the expansion of regulatory T cells
thus inducing immune suppression through a paracrine
effect. Interestingly, TEX display certain ligands, such
as programmed death-ligand 1 (PD-L1), to produce an
endocrine signaling effect to generate a favorable premetastatic TMaE extending a distance away from the primary tumor.
Exosomes have been widely studied in the recent years
as they were discovered to be a mechanism by which
tumor cells enhance progression and metastasis. We
have demonstrated that one pathway in creating a premetastatic niche is through TEX metabolically reprogramming normal fibroblasts and generating an acidic
microenvironment detrimental to immune function.
HMEX can reprogram the metabolism of normal stromal
fibroblasts by skewing the dominant metabolic process
from OXPHOS to aerobic glycolysis, encompassing the
Warburg effect and inducing extracellular acidification
that has been shown to contribute to a pre-metastatic
niche and a state of anergy of CD8+ T lymphocytes.
Other pathways include direct engagement of TEX with
receptors on immune cells as they express ligands that
engage receptors on T cells, including the T cell receptor
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(TCR) and IL-2 receptor (IL-2R) on T cells. TEX PD-L1
can suppress T cell activation and enhance tumor specific immune suppression. TEX inhibit the IL-2 proliferative response in CD8+ T cells and favor regulatory T
cell responses. TEX can also suppress monocyte maturation and generate a monocytic myeloid-derived suppressor cell phenotype (Mo-MDSC) that is favorable to
tumor escape from immune recognition. TEX may also
promote a pre-metastatic niche at a distant site through
blood and lymphatic drainage to promote vascular permeability, immunosuppression and metastasis. Exosome
distribution through the vascular and lymphatic systems
can allow TEX to enhance the TMaE beyond the immediate TME, extending the seed and soil hypothesis by
concluding that the soil may be prepared prior to seeding via cancer exosomes and their miRNA and protein
payloads. There, TEX act on normal stroma fibroblasts by
translocation of growth factor receptors and metabolic
reprogramming using microRNA payloads, promoting
a switch from oxidative phosphorylation (OXPHOS) to
aerobic glycolysis and an increase in extracellular acidification that contribute to the anergy of CD8+ T cells [16].
TEX are important messengers that enhance tumorigenesis and metastasis. They achieve this through a variety of mechanisms including immunosuppression, and
molecular and metabolic reprogramming that create a
pre-metastatic niche to facilitate the process of tumor
progression. Studies have shown that TEX not only influence the immediate TME, but they also travel to distant
tissue sites to establish a host-tumor “macroenvironment” through an endocrine phenomenon.
Low‑dose radiation and CAR T cell‑mediated in vitro
elimination of melanoma cells

A rapidly emerging immunotherapy approach called
adoptive cell transfer (ACT) is based on collecting and
using patients’ own immune cells to treat their cancer.
There are several types of ACT: TILs, TCRs, and CARs,
but, thus far, the one that has advanced the furthest in
clinical development is called chimeric antigen receptor
(CAR) T-cell therapy. The selection of appropriate target
antigens in solid tumors remains challenging for the therapeutic development of safe and effective CAR-T-based
therapies. The high expression of B7-H3 and chondroitin
sulfate proteoglycan 4 (CSPG4) across multiple tumor
types such as prostate, breast, placenta, liver, colon, and
lymphoid organs and restricted expression in normal tissues makes them attractive targets for immunotherapy.
CSPG4 is a cell surface type I transmembrane protein
critical for tumor progression and metastasis. B7-H3
(CD276) is an immune checkpoint from the B7 family of
ligands, many of whom interact with known checkpoint
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markers including CTLA-4, PD-1, and CD28 and it is
overexpressed in many cancer types.
Besides identification of a suitable tumor associated
antigen (TAA), trafficking of administered CAR T cells
to the tumor is another challenge to effective therapy. In
addition to the limited trafficking of CAR T cells to solid
tumors the mechanisms of resistance against CAR T
cell mediated killing includes immunosuppressive TME.
Consequently, experimental models to improve innate
CAR T cell trafficking via coexpression of chemokine
receptors have been developed. Therapeutic activity
of CAR-Ts can also be limited due to the rapid tumor
escape when the targeted antigen shows heterogeneous expression within the tumor, as recently reported in
patients with glioblastoma treated with CAR-Ts specific
for EGFRVIII. Increasing evidence suggests that intrinsic characteristics of CAR molecules, such as the epitope
recognized by the CAR and the affinity of the mAb from
which the CAR is derived, may play a significant role in
discriminating antigen recognition in normal versus
malignant cells.
BRAF mutation has been shown to downregulate
HLA class I and tumor antigen expression on melanoma
cells. Radiation upregulated B7-H3 and CSPG4 expression on BRAF wild type human MV3 melanoma cells
treated with a BRAF inhibitor. In BRAF-mutated human
M21 melanoma cells, radiation induced B7-H3 level but
there was limited modulation of CSPG4. Radiation also
upregulates HLA-A/B/C on human M21 melanoma
cells. Radiation seems to have a higher effect on BRAF
inhibitor-resistant cells compared to their BRAF inhibition-sensitive counterparts in terms of tumor antigen
upregulation and modulation of pro- and anti-apoptotic
molecules. Radiation upregulated B7-H3 expression on
human M21-R melanoma cells, resistant to BRAF inhibitors. In addition there was differential in vitro elimination
of both BRAF inhibitor sensitive and resistant melanoma
cells by B7-H3- or CSPG4-specific CAR T cells.
Radiation can render melanoma cells more sensitive to
CAR T cell-mediated lysis through upregulation of the
targeted tumor antigen, and imbalance between pro- and
anti-apoptotic molecules. At high effector to target cell
(E:T) ratio, there is no difference in terms of the cytotoxic effect of CAR T cells against BRAF inhibitor sensitive and resistant melanoma cells. However, at lower E:T
ratio, CAR T cells demonstrate more potent in vitro antitumor activity with irradiated BRAF inhibitor resistant
melanoma cells.
These data not only support the potential of achieving clinical benefits using CAR T cells in solid tumors
but also highlight that their antitumor activity can be
enhanced by radiation of target tumor cells.
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The model system for understanding checkpoint inhibitor
resistance in cancer

Immune checkpoint inhibitors have revolutionized
the treatment of patients with advanced-stage metastatic melanoma, as well as patients with many other
solid cancers, yielding long-lasting responses and
improved survival. However, a subset of patients who
initially respond to immunotherapy, later relapse and
develop therapy resistance (termed “acquired resistance”), whereas others do not respond at all (termed
“primary resistance”). Primary and acquired resistance
are key clinical barriers to further improving outcomes
of patients with metastatic melanoma, and the known
mechanisms underlying each involves various components of the cancer immune cycle, and interactions
between multiple signaling molecules and pathways.
Although there is a large body of literature on
response, the specific mechanisms of resistance and
biomarkers of resistance have not been well studied.
Overcoming therapy resistance requires a thorough
understanding of the mechanisms underlying immune
evasion by tumors. For an immunotherapy to elicit
an efficient antitumor immune response, the cancer
immune cycle must be initiated, and the subsequent
steps successfully completed. This involves efficient (i)
antigen presentation and T-cell activation, (ii) T-cell
trafficking and tumor infiltration, and (iii) T-cell killing
activity within the tumor microenvironment.
Studies examining possible predictive biomarkers of response to immunotherapy have reported a
higher density of preexisting cytotoxic T lymphocytes
in tumor biopsies of patients who displayed a greater
response to anti-PD-1/PD-L1 immunotherapy, and
more significantly, an increased influx of T cells and
PD-L1 macrophages early during treatment.
Patients with advanced melanoma with a favorable
prognosis tend to be those with low volume disease,
normal baseline LDH and a low number of metastatic sites. Tumors with high tumor mutation burden
(TMB) and high IFN-γ-gene expression profile (GEP)
both exhibit independent predictive value for response
to anti-PD-1 therapy, and represents the best tissuerelated predictive tool to date, although not clinically validated in prospective trials [17]. The analysis
of tumors across 22 tumor types including melanoma
from 4 KEYNOTE clinical trials showed that TMB and
inflammatory biomarkers (T cell-inflamed GEP and
PD-L1 expression) can jointly stratify human cancers
into groups with different clinical responses to pembrolizumab monotherapy. With this stratification in
mind, we can identify patterns of underlying, targetable
biology related to these groups. TMB and inflammatory
biomarkers independently predict response and may
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capture distinct features of neo antigens presence and
T cell activation, respectively.
Comprehensive clinical and genomic analysis demonstrated that TMB and IFN-γ expression independently
predicted response in 77 melanoma patients treated with
anti-PD-1 monotherapy or combined with ipilimumab
[18]. However, several patients did not fit this pattern as
they either responded despite having low TMB and IFN-γ
or had high TMB and IFN-γ but did not respond. These
patients are of particular interest in terms of understanding possible mechanisms of resistance.
In the clinic, patients who progress can be categorized
into four distinct primary progression groups: homogeneous and generalized with no benefit from therapy
(more common with immunotherapy than targeted
therapy), primary progression that is heterogenous and
solitary/oligometastatic, secondary progression after
an initial response (i.e. acquired resistance) that is heterogenous and solitary/oligometastatic, and secondary
progression that is homogeneous and generalized (more
common with targeted therapy). These clinical definitions can be used in prognostic models.
The resistance occurs when there is failure to induce an
effective antitumor immune response, as demonstrated
by primary or acquired resistance to immunotherapy in
melanoma. These two types of resistance are characterized by several molecular features.
1. Primary resistance patients have elevated levels of
baseline serum LDH, low tumor burden and lack of
PD-L1 expression in baseline melanoma tissue samples, lack of T-cell infiltration, the absence of PD-1 T
cells and PD-L1 macrophages in melanoma biopsies
taken early during treatments, insufficient neoantigens and low mutational burden, the presence of an
innate anti-PD-1 (IPRES) transcriptional resistance
signature, or absence of an interferon signature.
2. Acquired resistance occurs in patients who relapse
after exhibiting an initial response to immunotherapy.
An example of one such trait is beta-2-microglobulin
(B2M), a component of MHC class I molecules that is
necessary for their functional expression. The loss of
B2M expression was reported in melanoma cell lines
from five patients who had been treated with immunotherapy and cytokine-gene therapy. This resulted
in a loss of MHC class I expression and, therefore, a
subsequent decrease in recognition by CD8þ T cells.
JAK1/2 mutations have also recently been identified as genetic markers of acquired resistance to
immunotherapy in melanoma that is responsible
for cell proliferation, differentiation, cell migration,
and apoptosis. Other immune checkpoint markers
such as lymphocyte activation gene 3 (LAG-3) and
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T-cell immunoglobulin and mucin domain 3 (TIM-3,
HAVCR2) have also been revealed to interfere with
the activity of T cells, resulting in acquired resistance
to immunotherapy.
The research approach for molecular characterization
of underlying mechanism of resistance requires analysis
of biopsies at baseline, early during treatment and at disease progression. However, challenges in using advanced
melanoma as a model include heterogeneity of tumors,
with samples enriched for subcutaneous and lymph
nodes and limited sampling of other sites, quality issues
in sampling of metastases. An alternative model that
offers the advantages of abundant is homogenous resistant tumor tissue from neo-adjuvant trials. Several trials
are ongoing in the neoadjuvant setting with to provide
high quality matched clinical data and clear endpoints,
with the primary endpoint of pathological complete
response (CR) closely correlated with the secondary endpoint of long-term recurrence-free survival (RFS) [19].
Electrochemotherapy in integrated approach of metastatic
cutaneous melanoma

Electrochemotherapy (ECT) is an electroporation (EP)based technology used for clinical application and
research that includes drug delivery. Specifically, ECT is
a local and nonthermal tumor ablation modality, which
combines the administration of a poorly permeant cytotoxic agent with the local application of electric pulses
that induce reversible EP, thus improving drug diffusion
into the cells. ECT is performed using either intratumoral or intravenous cytotoxic drug injection, followed
by the application of electric pulses locally delivered to
the target tumor. ECT can be used when surgery is not
an option. ECT has comparable or superior effectiveness
over several ablative skin-directed therapies such as over
photodynamic therapy, radiotherapy, intralesional therapy, and topical therapy. Also, it can be used for chemotherapy-resistant and radiotherapy-resistant lesions. ECT
is suitable for patients with severe comorbidity and/or
patients of an advanced age who have already exhausted
all other treatments. Indications for its use in melanoma
include early cutaneous relapse after surgical treatment
and effective treatment of tumor lesions located in the
skin or subcutaneous tissue, both primary and metastatic. It has also shown its effectiveness in the case of
treating deep-seated tumors. ECT can be also used as
an alternative approach or as a palliative treatment after
standard therapies (such as surgery, radiotherapy, and
chemotherapy) to improve the quality of life for patients,
and as neoadjuvant therapy for extensive lesions or to
reduce the surgical approach. ECT can provide longterm benefit in terms of curative and palliative treatment
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for unresectable cutaneous lesions [20]. In a prospective
study of 376 patients with superficial metastases, tumor
response rate at 60 days was 88% (50% CRs) [21]. ECT
was also shown to be a highly effective local treatment
for melanoma metastases in the skin in an International
Network for Sharing Practices on Electrochemotherapy
(InspECT) trial that reported an objective response rate
(ORR) of 74%, 1-year OS of 67% and MSS of 74% [22].
Treatment was well tolerated with no serious adverse
events. Coverage of deep margins, previous irradiation of
the treated area and tumor size (< 3 cm) were positively
associated with a CR.
As with radiotherapy, ECT may induce an abscopal effect which suggests the potential for combining
with immunotherapy. This may result from releasing of
tumor antigens due to ECT treatment and induction of
inflammatory response, cytokine production, complement activation, increased MHC class I expression and
T cell activation resulting from checkpoint inhibition.
Retrospective analysis of 15 patients treated with ipilimumab who received ECT reported a local ORR of 67%
of patients (27% CR and a systemic response in 60% of
patients [23]. Evaluation of circulating regulatory T cells
(Tregs) demonstrated significant differences between
responders and non-responders. Overall, treatment was
well-tolerated. In 127 melanoma patients treated with
ipilimumab, the combination with local peripheral treatment (local irradiation, skin directed ECT or selective
internal radiotherapy of liver metastases) significantly
prolonged OS (93 vs. 42 weeks with ipilimumab alone)
[24]. Immune-related toxicities were not increased by
the combination and local peripheral treatment-induced
local toxicities were mostly mild. Overall, ECT appears to
be feasible and tolerable, with potent anti-tumor activity
and a high response rate, and the potential for use with
immunotherapy.
ECT is used currently for treatment of cutaneous and
subcutaneous lesions, without consideration of their histology. It is also becoming a practical method for treatment of internal, deep-seated tumors and tissues.
New perspectives in uveal melanoma

Uveal melanoma (UM), a rare subset of melanoma, is
the most common primary intraocular malignancy in
adults. Despite effective primary therapy, nearly 50%
of patients will develop metastatic disease. Outcomes
for those with metastatic disease remain dismal due to
a lack of effective therapies. Current immunotherapies
are less effective in UM than cutaneous melanoma. A
meta-analysis in patients with metastatic uveal melanoma treated with anti-PD-1/PD-L1s reported an ORR
of only 3.6% and a median PFS of 2.6 months [25]. These
poor results were confirmed in another meta-analysis,
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which showed a median PFS of 2.8 months in patients
receiving immunotherapy [26]. Results of single-agent
checkpoint blockade for UM have generally been disappointing. Dual checkpoint blockade with ipilimumab
and nivolumab in combination has achieved numerically superior outcomes to checkpoint blockade monotherapy; however, outcomes were still comparatively
poor. In a phase II, single-arm trial in 50 patients
with untreated metastatic UM, ORR was 12%, median
PFS 3.3 months and median OS 12.7 months [27].
Treatment-related adverse events were reported in 46
patients and nine patients discontinued treatment.
The differential response to checkpoint blockade
between uveal and cutaneous melanoma may, in part,
it can be explained by the unique biology and immunology of uveal melanoma that necessitates the development of dedicated management and treatment
approaches. The vast majority (85–95%) of uveal melanoma is characterized by activating mutations in genes
encoding the G-protein-alpha subunits GNAQ or
GNA11, which lead to stimulation of the MAPK and
phosphatidylinositol 3-kinase (PI3K)/Akt pathways.
Several other genetic alterations have been implicated
in the development of uveal melanoma. Inactivating
mutations in BAP1, a tumor suppressor gene located
on chromosome 3p, are found in approximately 47%
of primary uveal melanoma and 84% of metastatic
uveal melanoma cases, consistent with the association
between BAP1 mutations and poor prognosis. Mutations in splicing factor 3B subunit 1 (SF3B1), involved
in pre-messenger RNA splicing, while associated with
more favorable prognostic features than BAP1 mutations, are also found in cases of delayed metastasis,
with a median of 8.2 years. EIF1AX encodes for eukaryotic translation initiation factor 1A. These mutations
are mutually exclusive from BAP1 and SF3B1 and are
associated with a longer disease-free survival and a
more favorable prognosis
Furthermore, metastatic UM are characterized by the
low mutational burden observed in uveal melanoma may
partly account for the limited success of immune checkpoint blockade. Moreover, upregulation of immunosuppressive factors such as Indoleamine 2,3-dioxygenase
(IDO1) and T cell immunoreceptor with Ig and ITIM
domains (TIGIT) may contribute to treatment resistance
and suggests a role for combination immune therapies
targeting these additional factors. There is a significant
decrease in PD-1-positive lymphocytes and lower levels of PD-L1 in metastatic uveal melanoma compared
with cutaneous melanoma metastases. Tumors from
metastatic UM patients also show a lower rate of tumorinfiltrating lymphocyte (TIL) expansion compared with
metastatic cutaneous melanoma [28].
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However, while uveal and cutaneous melanoma diverge
in many features, phenotypic commonalities such as
expression of the melanoma-associated antigen gp100
remain. Data from The Cancer Genome Atlas (TCGA)
show that transcript expression of gp100 is observed
in both with more uniformly high expression of gp100
transcript in primary uveal melanoma compared with
compared primary cutaneous melanoma. Tebentafusp
(IMCgp100) is a bispecific biologic in development by
Immunocore, comprising targeting and effector moieties. The targeting end constitutes a soluble T cell receptor (TCR) that recognized the melanocyte-associated
antigen glycoprotein 100 (gp100) presented in the context of HLA-A2, which is expressed in approximately
50% of patients with uveal melanoma, and the effector
end includes an anti-CD3 single chain variable fragment (scFv). In vitro, IMCgp100 redirects a potent T
cell-mediated immune response toward gp100 positive
melanoma cells. In a phase I trial, 3/17 (18%) patients
with metastatic uveal melanoma achieved a PR and 11/17
(65%) achieved disease control for ≥ 16 weeks. OS rates
at 1 year of 74% (95% CI 48–88) were also achieved [29].
Two potential explanations for the apparent beneficial
effect of tebentafusp in uveal melanoma are that gp100
expression is particularly high in this tumor type and that
recruiting T cells to antigen-positive sites and inducing
an inflammatory response in the presence of a relatively
non-T cell-inflamed genetic signature might help overcome this barrier. The therapeutic advances that have
translated to improved patient survival in cutaneous
melanoma have unfortunately not yielded similar benefits in advanced uveal melanoma. However, ongoing
efforts seek to optimize the efficacy of targeted therapy
and immunotherapy in both the adjuvant and metastatic
setting.

Session—mechanism of resistance and drivers
of response
Translational research in the metastatic melanoma: recent
results

Cell invasion through the basement membranes is crucial during morphogenesis and cancer metastasis. The
basement membrane is a dense, highly cross-linked,
sheet-like extracellular matrix that underlies all epithelia and endothelia. During development of metastatic
disease, cells cross the basement membrane to disperse
and enter new tissues. This complex invasive process
depends on a coordinated network of polarization, the
production of matrix metalloproteinases, breaching of
the basal membrane and the formation of invadopodialike structures. The transmembrane migration of cancer
cells recapitulates the penetration of epithelial cells during development.
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Models to study basal membrane breaching include
chick chorioallantoic membrane, drosophila imaginal
discs, studies of leukocyte transmigration in vertebrates
and intravital imaging studies in murine tumor models
and anchor cell invasion in the nematode Caenorhabditis
elegans. Anchor-cell invasion in C. elegans is a simple and
attractive model of regulated cell-invasive behavior.
Importantly, the pre-replication complex including
cyclin-dependent kinase CDKN2A is an essential component during basal membrane disruption. Several components of the DNA pre-replication complex are required
for anchor cell invasion. Three genes required for normal anchor cell invasion encode cell cycle regulators:
cell division cycle 6 (CDC6) ATP binding protein is an
essential component of the DNA pre-replication complex, CYD-1 encodes the only cyclin D homolog in C. elegans and cyclin-dependent kinase 12 (CDK12) encodes
the CDK required for activation of RNA polymerase II.
The pre-replication complex controls actomyosin polarity and pro-invasive gene expression in the G1-arrested
anchor cell.
The acquisition of invasive behavior also marks a critical transition during melanoma progression [30]. The
study provides direct evidence that this ability is promoted by increased cellular motility and migration of
neoplastic melanocytes from the epidermis into the subjacent dermis that results from CDKN2A loss. The most
common acquired genetic change distinguishing precursor lesions, such as melanocytic nevi or melanoma in situ
(MIS), from invasive melanomas is loss of the CDKN2A
locus. The CDKN2A locus encodes two gene products—p14ARF and p16INK4A—each under transcriptional regulation by independent promoters and each
with distinct tumor suppressive functions. The loss of
p16INK4A promotes melanocyte motility and the invasive and metastatic capacity of melanoma cells through
the transcriptional activation of BRN2, a transcription
factor previously associated with melanocytic invasive
programs during both development and disease was
demonstrated [31]. Loss of p16INK4A promotes melanocyte motility and the invasive and metastatic capacity of
melanoma cells through the transcriptional activation of
BRN2, a transcription factor previously associated with
melanocytic invasive programs during both development
and disease. Targeting of the pre-replication complex is a
promising approach for chemoprevention of melanomas
and other cancers.
Intrinsic tumor genomic and metabolic factors leading
to immunoresistance

Significant progress has been made in the field of cancer immunotherapy however, durable responses are only
achieved in a subset of patients, and currently there is
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very limited ability to predict whether a patient is likely
to respond to immunotherapy. Recently, several studies
have elucidated some of the tumor intrinsic molecular
mechanisms of resistance to immunotherapy. Tumors
use various mechanisms to evade the immune system
that involve avoiding detection, promoting an immunosuppressive microenvironment, and resisting cell death.
For example, tumor cells can avoid detection through
B2M loss and class I down regulation (Fig. 1).
RNA-binding protein MEX3B was identified as a candidate protein whose overexpression in melanoma cells
decreased their susceptibility to killing by autologous TIL
in vitro suggesting that it mediates resistance to cancer
immunotherapy. Overexpression of MEX3B in melanoma cells decreased IFN-γ release by autologous TILs
and downregulated HLA-A expression [32]. Downregulation of HLA-A expression by MEX3B is a novel mechanism for tumor cells to evade attack by T cells. Analysis
of anti-PD-1 treated melanoma patient tumor samples
suggested that higher MEX3B expression is associated
with resistance. Our findings have the potential to lead
to the development of therapeutic strategies targeting
MEX3B in hope of overcoming immunoresistance and
achieving better clinical outcomes for patients with melanoma treated with immunotherapy.
Tumor cells can also produce a microenvironment that
inhibits immune cells. Tumor induced immunosuppression by transforming growth factor‐β (TGF‐β), a cytokine
with pleiotropic effects on cell growth and differentiation is known mechanism of immunotherapy resistance.
We hypothesize that truncating the intracellular domain
of the TGF‐β receptor will abrogate immunosuppressive signalling through this pathway, which may augment
immunotherapy effectiveness. Preclinical studies showed

Fig. 1 Mechanisms tumors use to resist the immune system:
avoided detection, production of inhibitory microenvironment, death
resistance
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safety and efficacy of virally transducing T cells with
TGF‐DNRII and improved proliferation and function
of T cells. Treatment with TILs engineered to express
TGF-β DNR and nerve growth factor receptor (NGFR)
(which is truncated to render it incapable of signalling,
serves as a control) resulted in best imaging response by
irRC that was PD/SD/PR in 1/5/1 pts with DCR of 86%.
All 5 SD patients have had disease reduction of 12–48%
with responses ongoing. The PR patients continues to
respond 15 months after therapy. There was no added
toxicity from the gene modified TIL with toxicities attributed to lymphodepletion and IL‐2. Genetic modification
of TIL with TGF‐DNRII is feasible to generate, safe to
administer and has demonstrated efficacy in malignant
melanoma. [8].
Loss of the tumor suppressor gene phosphatase and
tensin homolog (PTEN) inhibits T cell infiltration into
tumors and has been found to correlate with resistance
to anti-PD-1 in melanoma patients [33]. We recently
demonstrated that loss of PTEN impedes trafficking
of effector T cells to tumors, reduces the sensitivity of
melanoma cells to T cell mediated killing, and correlates
with inferior outcomes in patients treated with immune
checkpoint blockade. Treatment with a selective PI3Kβ
inhibitor improved the anti-tumor activity of anti-PD-1
in a genetically engineered PTEN loss tumor model.
Recent studies also identified glycolysis as a candidate
pathway of resistance. Immuno-resistant PTEN-silenced
tumors display increased glycolytic activity [34]. Upregulated expression levels of glycolysis-related genes were
associated with poor T-cell infiltration in melanoma and
NSCLC tumor samples. Overexpression of glycolysisrelated enzymes impaired T cell killing of tumor cells,
whereas inhibition of glycolysis enhanced T cell-mediated antitumor immunity in vitro and in vivo. Inhibition
of glycolysis enhanced efficacy of adoptive T-cell therapy
(ACT) and increased glycolytic activity was detected in
cell lines from melanoma patients non-responding to
ACT. Reduced expression of IRF1 and CXCL10 immunostimulatory molecules was observed in highly glycolytic melanoma cells. These findings indicate that
increased tumor-intrinsic glycolytic activity is associated
with poor tumor migration of T cells and reduces susceptibility of tumors to T cell induced apoptosis. Critical
role of tumor intrinsic glycolysis in modulating T cellmediated antitumor activity may lay foundation for the
development of glycolysis inhibitors to improve the effectiveness of ACT for cancer treatment.
Tumor mutation burden and liquid biopsies: helpful
for treatment decisions?

Localized and advanced cancers may generate circulating tumor cells and circulating cell free tumor DNA
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(ctDNA) that can be detected and quantified from
peripheral blood samples (liquid biopsy). For melanoma
patients, liquid biopsy results may serve as novel predictive biomarker to guide therapeutic decisions, particularly in the context of mutation-based targeted therapies.
Tumor mutation burden (TMB) is a potential biomarker
for immunotherapy response and early measurement
of circulating tumor ctDNA can help to detect treatment failure to immunotherapy. However, it has not yet
been clarified how TMB and ctDNA can be used to estimate response to combined CTLA-4 and PD-1 antibody
therapy in metastatic melanoma. Novel detection technologies have significantly improved the sensitivity and
specificity of the ctDNA detection assays as due to the
low abundance of ctDNA, its detection requires highly
sensitive and specific techniques. The analysis of ctDNA
provides three parameters that may be correlated with
clinical outcome: (1) the total quantity of ctDNA in the
sample, (2) the molecular fingerprint of the ctDNA by
mutation detection, and (3) the quantification of mutant
copy numbers. Three of the most frequently used techniques are digital PCR (dPCR), BEAMing and allelespecific ligation PCR (LPCR). The clinical implications
of liquid biopsy in routine diagnostic testing of melanoma patients is promising. In a prospective biomarker
study, 35 melanoma patients treated with ipilimumab
and nivolumab were assessed using a tumor panel of 710
tumor-associated genes followed by repeat liquid biopsies [35]. Tumor mutational burden (TMB) was higher
in responders than in non-responders and TMB > 23.1
Mut/Mb (TMB-high) was associated with a melanomaspecific survival (MSS) benefit compared to TMB ≤ 23.1
Mut/Mb (TMB-low or TMB-intermediate). Liquid biopsies every 3–4 weeks were taken for analysis of ctDNA
using targeted gene panel for sequencing. At first followup 3 weeks after treatment initiation, increased ctDNA
concentration was observed more often in non-responders and a > 50% decrease in ctDNA was significantly
associated with response to combined immunotherapy.
A > 50% increase in ctDNA, or detectable/increasing
ctDNA at first follow-up were significantly associated
with worse OS while patients with high TMB showed
a trend towards prolonged survival. OS was worse in
patients with TMB ≤ 23.1 Mut/Mb and either ctDNA
increase/detectable or ctDNA increase of > 50% at first
follow-up. Liver metastases also had a significant negative impact on response and there was a trend towards
lower response rate with elevated lactate dehydrogenase
(LDH), previous targeted therapy and PD-L1 expression
< 1%.
Other reports have suggested ctDNA can be predictive of response to anti-PD-1 therapy in metastatic melanoma. Longitudinal assessment of ctDNA in 76 patients
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receiving treatment with PD-1 inhibitors was an accurate
predictor of response, PFS and OS [36].
The use of liquid biopsy in routine diagnostic testing remains limited due to the following challenges: (1)
clonal heterogeneity, e.g. the detected ctDNA might not
represent the predominant tumor clone, thus the progression of the major clone might be overlooked, (2) not
defined origin of ctDNA (primary, metastatic, or premalignant lesion; or (3) different cancers developing during
the course of disease/treatment.
Localized and advanced cancers may also generate
circulating tumor cells (CTCs) that are detectable in the
blood. CTCs show promising results in establishing the
tumor response to chemotherapy and in the prognosis of
cancer patients. Numerous assays for the direct detection
of CTCs have been developed that allow for the analysis
of CTCs at the single-cell stage in the peripheral blood.
In a study of 84 patients with malignant melanoma, a
combined analysis of ctDNA and CTCs predicted relapse
earlier than imaging and was more accurate than serum
LDH or S100 in a subset of patients [37]. Overall, 32% of
patients were CTC-positive. An increase in CTC-positive patients was detected with increased tumor staging. Analysis of CTCs count and ctDNA < 150 bp appear
to be promising to predict tumor burden in melanoma
patients, as negative values may indicate a complete
remission.
Although the clinical relevance of CTCs and ctDNA for
disease monitoring in patients with metastatic disease is
well known and currently entering routine clinical diagnostic use, the role of these biomarkers in early-stage
cancer patients remains to be investigated.
Primary and secondary mechanisms of immunotherapy
resistance

The immune system has the potential to recognize and
eliminate tumor cells, and failed immune surveillance
contributes to cancer development. Many immunotherapeutics, including checkpoint blockade therapy, harness
the endogenous antitumor immune response. While clinical benefit can be profound, some patients show primary
resistance, whereas others experience clinical response
and then develop secondary resistance. General mechanisms include adaptive evasion, allowing the tumor to
establish equilibrium with an existing T cell infiltrate,
and innate evasion, in which T cells and other immune
cells are excluded from the tumor microenvironment.
Clinical studies have indicated that tumors lacking a baseline infiltrate of activated T cells typically
fail to respond to checkpoint blockade therapy. For
T cell-inflamed tumors, multiple mechanisms have
been implicated in defective T cell-mediated tumor
elimination. T cells that do effectively home to tumor
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metastases (based on chemokine gradients and activated vascular endothelial cells) may become dysfunctional, pointing toward immunosuppressive
mechanisms in the tumor microenvironment. T cell
anergy due to insufficient B7 co-stimulation, extrinsic
suppression by regulatory cell populations, inhibition
by ligands such as programmed death ligand-1 (PD-1),
metabolic dysregulation by enzymes such as indoleamine-2,3-dioxygenase (IDO), and the action of soluble
inhibitory factors such as transforming growth factor-β
(TGF-β) have all been reported to contribute to this
suppressive microenvironment. This suggests the paradigm of restoring CD8+ T cells already in the tumor
through blocking negative regulation.
Gene expression signatures based on the T cellinflamed phenotype in the tumor microenvironment
are associated with the presence of an adaptive immune
response and clinical benefit from PD-1/PD-L1 blockade
[38]. This signature was developed on the NanoString
nCounter gene expression system (NanoString Technologies, Inc., Seattle, WA) in the context of pembrolizumab
treatment as a pan-tumor determinant of response to
PD-1 directed therapy. Samples were obtained at baseline
from patients undergoing treatment with pembrolizumab
in clinical trials of multiple distinct tumor types in a rigorous stepwise validation of the hypothesis that immunerelated gene signatures can enrich for clinical response to
PD-1 checkpoint blockade.
Another potential biomarker relevant to a broad spectrum of tumors is measurement of total tumor mutation
burden (TMB). The correlation of TMB and response
to checkpoint inhibitors was demonstrated in lung cancer, which has a broad range of nonsynonymous mutations within the tumor. Overall, tumor types with higher
median mutation burden tend to be more responsive to
checkpoint inhibitors than tumors that harbor few mutations. The earliest successes of checkpoint inhibitors
were in melanomas and non-small cell lung cancers, two
tumor types that can have high mutation burden due to
mutagen exposure (UV light and tobacco smoke).
Multiple tumor cell-intrinsic oncogenic events may
contribute to primary or acquired resistance to immunotherapy. The WNT-β-catenin pathway appears to be
associated with a non-T cell-inflamed TME, as β-cateninpositive tumors had minimal T cell infiltration and have
been shown to be more resistant to checkpoint blockade
therapy. Specifically, tumor cell-intrinsic β-catenin activation prevents host anti-tumor immune response by
failure to recruit Batf3-leneage DCs, which are involved
in both the priming phase and the effector phase of antitumor immune response [39]. Batf3-DCs in the tumor
microenvironment (TME) are also necessary at the time
of anti-PD-L1 therapeutic effect. Batf3+ DCs clustering
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with CD8+ T cells in tumors correlate with a positive
IFN-γ gene-signature.
Beyond β-catenin, gene deletions and loss-of-function
mutations of the tumor suppressor phosphatase and
tensin homolog (PTEN) have also been associated with
poor T cell infiltration in the tumor microenvironment
in metastatic melanoma. Loss of PTEN, which leads to
increased activation of the phosphatidylinositol 3-kinase
(PI3K)–Akt pathway, has been associated with primary
and secondary resistance to PD-1 blockade in melanoma [40]. Features of T cell-inflamed TME can serve as
predictive biomarkers for response to anti-PD-1-based
immunotherapies. Primary resistance to checkpoint
blockade in most cases is associated with the absence
of a T cell inflamed TME. Non-T cell-inflamed tumors
have no shortage of antigens, but lack Batf3-lineage
DCs. T cell exclusion from the TME can be mediated by
β-catenin, PTEN loss, and other oncogenic events. Secondary resistance to immunotherapies can arise upon
selection for new oncogenic variants that mediate T cell
exclusion. Two oncogenic events linked to poor T cell
infiltration and secondary immunotherapy resistance
are tumor cell-intrinsic β-catenin pathway activation and
PTEN loss-of-function mutation or deletion.
Next target for immune checkpoint blockade: Tim‑3
in cancer immunotherapy

Multiple negative immunoregulatory pathways impede T
cell-mediated tumor destruction in the tumor microenvironment (TME), contributing to the paradoxical coexistence of TA-specific CD8+ T cells and tumor progression
in cancer patients. Among them, inhibitory receptors
(IR) like PD-1 and CTLA-4 play a critical role in dampening T cell functions. Immunotherapies with immune
checkpoint inhibitors directed against these immunoregulatory pathways provide long-term clinical benefits to
patients with a growing range of solid tumors. Exhausted
T cells upregulate a large number of these receptors,
including PD-1, CTLA-4, T cell immunoglobulin domain
and mucin domain containing-3 (Tim-3) also known as
Hepatitis A virus cellular receptor 2 (HAVCR2), lymphocyte activation gene 3 (LAG-3), and T cell tyrosinebased inhibitory motif domain (TIGIT). These inhibitory
receptors are expressed by a significant number of tumor
antigen-specific T cells, with ligands highly expressed in
the TME. There is evidence of additive/synergistic effects
on tumor antigen specific CD8+ T cell expansion, supporting the concept of dual blockade through combined
therapeutic approaches to improve the efficacy of the
treatment.
Tim-3 is an important negative regulator of innate
and adaptive immunity. In cancer, PD-1+Tim-3+ CD8+
T cells are dysfunctional/exhausted. Notably, TIM-3
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appears to be an adaptive mechanism of resistance to
PD-1 blockade in mouse lung tumor models. Besides
CD8 TILs, TIM-3 is also expressed on Tregs and multiple innate immune cell types, including NK cells and
APCs. Tim-3+ Fox3+ Tregs, represent a subset of highly
activated/suppressive Tregs, which also express highlevel PD-1, CTLA-4, and LAG-3. The binding of Tim-3
to phosphatidylserin promotes the uptake of apoptotic
cells and cross-presentation of antigen by dendritic cells,
which constitutively express high-level Tim-3. Multiple
ligands can bind to Tim-3, including galectin 9, Phosphatidylserin, CEACAM-1 and HMGB1. The role of
these ligands in mediating Tim-3-mediated immunosuppression in human cancers remain to be elucidated.
Preclinical data have shown that dual blockade of
PD-1 and TIM-3 augments tumor antigen-specific
cell responses in vitro with evidence of reduced tumor
growth in vivo. These data suggest that the PD-1 and
TIM-3 pathways promote T cell dysfunction in a nonredundant fashion. They also support that dual blockade
of PD-1 and TIM-3 reinvigorates effector T cell responses
more potently than single blockade. In a murine model
of breast cancer, TIM-3 expression appeared to regulate
the function of CD103+ DCs through CXCL9 expression
[41]. Anti-TIM-3 antibody indirectly enhanced a CD8+
T cell response during chemotherapy. Anti-TIM-3 or
anti-galectin 9 antibody increases CXCL9 expression by
DCs. Therapeutic efficacy was ablated by CXCR3 blockade, Batf3 deficiency, or Irf8 deficiency.
Dual blockade of PD-1 and Tim-3 has shown evidence
of clinical activity with manageable toxicity in PD-1
refractory NSCLC and melanoma patients [42]. Objective
responses observed were in PD-L1-positive (TPS ≥ 1%)
patients, indicating the potential for biomarker enrichment. This combination is being further assessed in several clinical trials.
Histopathologic assessment of pre‑ and on‑treatment
specimens for predicting response to anti‑PD‑(L)1 therapy

Anti-PD-(L)1-based therapies have shown remarkable
effects in patients with advanced cancers, and may also
improve outcomes for patients with resectable cancers.
The neoadjuvant setting also provides a critical window
for examining pathologic response features within the
resected tumor. Pathologic response is a possible surrogate for long-term outcomes, and thus examination
of the definitive resection specimen for residual viable
tumor (RVT) can potentially be used to predict clinical
benefit after weeks or months after therapy initiation,
rather than waiting a years for overall survival data to be
resulted. As such, it can be used to help guide therapeutic adjustments on both an individual patient-level and
immunotherapy field-level. Numerous clinical trials for
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neoadjuvant immunotherapy are underway and many
of these include assessments of pathologic response
(e.g. pathologic complete response [pCR], i.e. 0% RVT,
or major pathologic response [MPR] i.e. ≤ 10% RVT) as
proposed endpoints. Scoring of pathologic response was
first developed for neoadjuvant chemotherapy. Chemotherapy and immunotherapy have distinct mechanisms
of action and thus, they have distinct histologic features
of response, necessitating the development of a new scoring system. To meet that need, Cottrell, et al. developed
a proposal for immune-related pathologic response criteria (irPRC) using hematoxylin and eosin-stained slides
from the definitive resection specimens and routine light
microscopy [43]. Features of immune-mediated tumor
regression included dense tumor infiltrating lymphocytes, foamy macrophages, and tissue repair (neovascularization and proliferative fibrosis), amongst others.
Specific attention was paid to ensure that the histologic
areas studied for features of residual viable tumor or evidence of immune-mediated regression were correlated
with the pre-resection radiographic ‘tumor’ measurements. The proposed irPRC was then tested for interobserver reproducibility amongst 5 pathologists and
showed very high reproducibility at 10% intervals of
residual viable tumor with an interclass coefficient > 0.9
[43]. Similar histologic features have since been reported
in specimens from patients with melanoma and many
other solid tumor types that were treated with anti-PD-1based therapies in the neoadjuvant setting [43]. The main
goal in the development of such a histology based scoring
system is to predict long-term survival after only a few
weeks on therapy. The data in the neoadjuvant setting
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is not yet mature enough to correlate the observed histologic features with 5 year patient outcomes. However,
these same histologic features are observed in immunemediated tumor regression in patients with advanced
disease treated with anti-PD-1 based therapy, where data
on long-term follow up is available. To test the association of these features with survival, irRPC was used to
score pathologic response in early on-treatment biopsy
specimens (taken 2–4 weeks after therapy initiation)
from patients with melanoma. Patients with a major
pathologic response on biopsy (MPRbx; < 10% residual
viable tumor) showed significantly improved 5-year overall survival, compared to those with a larger proportion
of RVT [43] (Fig. 2) Ongoing analyses include in-depth
assessment of individual histologic features observed in
these hematoxylin and eosin-stained specimens, as well
as clinically meaningful thresholds of RVT beyond pCR/
MPR in on-treatment specimens. Taken together, these
findings lend support to the idea that irPRC will be predictive of OS in the neoadjuvant setting. They also suggest that early on-treatment H&E biopsies for patients
advanced setting may have clinical utility in indicating a
response to therapy, weeks before radiographic evidence
is present.

Session—emergent strategies
Promising treatment strategies in early development

Interleukin-1 (IL-1) has been known to be a key mediator of immunity and inflammation. Its dysregulation has
been implicated in tumorigenesis and tumor progression, and its upregulation is thought to be associated
with many tumors. Overexpression of the IL-1 agonists

Fig. 2 Major pathologic response assessed on biopsy, rather than definitive surgical resection
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IL-1a and IL-1b has been shown to promote tumor invasiveness and metastasis by inducing the expression of
angiogenic genes and growth factors. Tumor IL-1 signaling is also involved in resistance to immunotherapy
and immune evasion with robust evidence in NSCLC
and pancreatic cancer. IL-1 receptor accessory protein
(IL1RAP) is required to activate IL-1 receptor signaling. IL1RAP is expressed in several solid tumors, both
on cancer cells and tumor-associated inflammatory cells.
IL-1β blockade with canakinumab significantly reduced
incidence of lung cancer in the CANTOS trial [44].
CAN04 (nidanilimab) is a humanized IgG1 monoclonal
antibody targeting IL1RAP, blocking IL-1α and β signaling and triggering antibody-dependent cellular cytotoxicity (ADCC). Preclinical data in a NSCLC patient-derived
xenograft model showed synergistic effects between
CAN04 and cisplatin/gemcitabine. In a phase IIa trial,
CAN04 was well tolerated with infusion-related reactions the most frequent adverse event in patients with
various solid tumors [45]. A recommended phase 2 dose
of 10 mg/kg was established. The dose expansion phase
of the trial will evaluate CAN04 as monotherapy as well
as in combination with cisplatin/gemcitabine in NSCLC
and gemcitabine/nab-paclitaxel in pancreatic ductal
adenocarcinoma.
The STING pathway senses intracellular DNA, triggering an immediate production of type I IFN. STING
activation has wide-ranging impact on both the innate
and adaptive immune response by inducing antigenpresenting cell recruitment and priming CD8+ T cells
against tumor antigens. MIW815 (ADU-S100) is a synthetic cyclic dinucleotide (CDN), a first-in-class STING
agonist. MIW815 (ADU-S100) has shown efficacy in
combination with PD-1 checkpoint inhibitors and elicited near complete clearance of injected and non-injected
tumors in mice. In a phase 1b combination trial of intratumorally administered MIW815, a novel synthetic cyclic
dinucleotide that activates the STING pathway, and spartalizumab, a humanized IgG4 monoclonal antibody that
blocks the binding of PD-1 to PD-L1/2 [46]. Data from
83 patients with advanced/metastatic solid tumors or
lymphoma were evaluated. The most common primary
diagnoses were melanoma (42.2%) and triple-negative
breast cancer (13.3%). Most patients (72.3%) received
prior immunotherapy. No dose-limiting toxicities were
reported in any of the dosing cohorts and adverse events
with the combination were no more frequent or severe
than those reported with either single-agent. Systemic
IFN-β levels appeared to increase in a dose-dependent
manner and a trend was observed between IFN-β levels
and systemic exposure. Other cytokines detected (IP-10,
MCP-1, and IL-6) did not demonstrate significant dose
dependency and/or PK/PD relationships. CD8 frequency

Page 15 of 22

as detected by IHC increased in responding patients with
high PD-L1 at baseline. The combination of MIW815
and spartalizumab demonstrated antitumor activity in
PD-1-naïve patients with TNBC and patients with anti
PD-1-relapsed/refractory melanoma. Five patients in
the MIW815 weekly-dose cohort achieved confirmed
responses, including one complete response. Three
of these responses, including the complete response,
occurred among patients with immunotherapy-naive
triple-negative breast cancer, two of whom had PD-L1
expression greater than 1% at baseline. The other two
responders had previously received immunotherapy.
These findings are promising as the combination was
well-tolerated, with no dose-limiting toxicities reported
to date and demonstrated anti-tumor activity.
Adjuvant therapy for high‑risk melanoma—current status

Most patients with stage III (lymph node positive) melanoma are offered adjuvant therapy, although if only one
node is involved with very small amounts of melanoma
(< 1 mm) some centers elect observation. Ipilimumab
was the first successful checkpoint inhibitor in metastatic
melanoma and has also been shown to be effective in the
adjuvant setting. However, adjuvant treatment with ipilimumab is associated with significant toxicity, especially
since the adjuvant dose is three-fold higher than the
metastatic dose. The toxicity of ipilimumab indicates that
nivolumab and pembrolizumab may be preferred as adjuvant treatment. In the CheckMate-238 trial, the 1-year
rate of RFS was 70.5% with nivolumab versus 60.8%
with ipilimumab (HR for disease recurrence or death,
0.65; 97.56% CI 0.51–0.83; P < 0.001) [7]. Treatmentrelated grade 3–4 adverse events were reported in 14%
of patients treated with nivolumab versus 46% of patients
treated with ipilimumab. Similarly, pembrolizumab significantly increased 1-year rate of RFS versus placebo
(HR for recurrence or death, 0.57; 98.4% CI 0.43–0.74;
P < 0.001) with 15% of pembrolizumab patients experiencing treatment-related grade 3–5 adverse events
[6]. Targeted therapy with BRAF/MEK inhibitor combinations are also effective as adjuvant therapy, with an
estimated three-year RFS rate of 58% observed with dabrafenib plus trametinib versus 39% with placebo (HR for
relapse or death, 0.47; 95% CI 0.39–0.58; P < 0.001), and
so represent a new standard of care for BRAF-positive
patients.
Immunotherapy with anti-PD-1 agents is effective in
adjuvant therapy for all high-risk melanoma patients
while BRAF/MEK targeted therapy is effective for highrisk patients with BRAF mutation. Present clinical trialbased evidence suggests that both targeted agents and
anti-PD-1 agents derive clinical benefit and a tolerable
profile in the adjuvant setting in BRAF-mutant patients.
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However, there is no long-term (> 4 years) head-to-head
comparison. Targeted agents involve daily oral administration versus IV infusion every 2–4 weeks with antiPD-1 therapy. Toxicity with BRAF/MEK inhibitors
can be chronic but manageable and can be reversed by
treatment interruption, while toxicity with anti-PD-1s
is uncommon but can be severe and may not always be
reversible.
Findings from ongoing adjuvant trials are eagerly anticipated. These include two US Intergroup studies, the
E1609 trial of ipilimumab 3 or 10 mg/kg versus high-dose
IFN and the S1404 trial of pembrolizumab versus highdose IFN or ipilimumab 10 mg/kg, and the CheckMate
915 trial of combined nivolumab plus ipilimumab versus
nivolumab monotherapy. Several clinical trials are ongoing, using nivolumab and pembrolizumab in monotherapy or in combination with chemotherapy, radiotherapy,
other immunotherapies, and targeted therapies. Depending on the molecular features of the patients and tumors,
as well as the responses to therapy, personalized treatment should be considered for melanoma patients, in
order to achieve better clinical benefits. Further research
is necessary to explore oncogenic pathways and the TME
potential in the treatment of melanomas.
Neoadjuvant immunotherapy—the pathway to therapy
personalization

Locally/regionally advanced melanoma confers a major
challenge in terms of surgical and medical management.
Surgical treatment carries the risks of surgical morbidities and potential complications that could be lasting. In
addition, these patients continue to have a high risk of
relapse and death despite the use of standard adjuvant
therapy. Neoadjuvant therapy has the potential to significantly improve the clinical outcome of these patients,
particularly in this era of newer and effective targeted
and immunotherapeutic agents. Several neoadjuvant targeted and immunotherapy studies have been completed
in melanoma to date and have yielded promising clinical
activity.
Potential benefits of neoadjuvant immunotherapy
include reduction in tumor burden before surgery with
improvements in surgical resectability, organ preservation, and improvement in overall survival (OS). In
addition, pathological response evaluation can serve as
surrogate outcome markers for RFS and OS in addition
to clinical and radiologic responses, and stronger and
broader tumor-specific T cell responses may be induced.
Nonresponding patients however may deteriorate before
potential curative surgery, which might also be impaired
by immune-related adverse events.
Neoadjuvant studies provide access to blood and
tumor biospecimens before and during systemic therapy,
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supporting studies of immunologic and histologic correlates of tumor response. Such studies can allow for better understanding of the antitumor mechanisms of action
and ultimately would enable more selective application
of therapeutic agents to patients who are more likely to
benefit.
In the OpACIN study, neoadjuvant ipilimumab plus nivolumab did not delay surgery and the
pathologic response rate was high (78%) but treatment
was highly toxic with 90% grade 3–4 adverse events. Also,
higher frequency of tumor resident T cell receptor (TCR)
clones was observed in neoadjuvant treated tumors [47].
In the phase II OpACIN-neo trial to identify the optimal neoadjuvant combination scheme of ipilimumab
and nivolumab, two cycles of ipilimumab 1 mg/kg plus
nivolumab 3 mg/kg was tolerated and induced a pathological response in a high proportion of patients [48].
In a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC), neoadjuvant
immunotherapy and targeted therapy showed efficacy in
resectable clinical stage III melanoma patients and were
associated with high pCR rate [19].
In both the OpACIN and OpACIN-neo trials, no
patients with a pathologic response had relapsed after
a median follow-up of 30 and 8.3 months, respectively.
In stage IV melanoma, long-term benefit is observed in
patients achieving CRs with immune checkpoint inhibition, even after cessation of therapy. This raises the
question of whether complete lymph node dissection
(CLND) can be omitted when a complete pathologic
response with neoadjuvant immunotherapy is achieved.
The aim of the phase II PRADO study is to confirm the
pathological response rate and toxicity of neoadjuvant
ipilimumab plus nivolumab. Additional aim is to determine subsequent therapy i.e. omitting surgery and adjuvant nivolumab based on the pathological response. The
pathologic response in the largest lymph node can be
considered a reliable indicator of therapeutic response
to neoadjuvant immunotherapy in patients with stage III
melanoma [49]. To date, the PRADO trial demonstrated
that pre-treatment biomarker analysis in index lymph
node as well as pathologic evaluation of the marked
lymph node is feasible.
These results describe the feasibility of neoadjuvant
immune checkpoint blockade in melanoma demonstrating that neoadjuvant immunotherapy may be superior
to adjuvant immunotherapy. However, neoadjuvant may
not offer benefit over adjuvant therapies to all patients
because it induced high toxicity rates; therefore, it needs
to be further investigated to balance efficacy and toxicity.
Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders. Personalization of neoadjuvant immunotherapy based on
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DNA/RNA signatures and personalization of surgical
extent may become a standard.

press - relea s e/corpo r atef i nanc i al-news/brist o l-myers
-squibb-announces-update-checkmate-915-opdivo-niv).

What combinations are really worth it?

Therapeutic targets in non‑T cell‑inflamed tumors

Nivolumab plus ipilimumab show a sustained long-term
benefit with 5-year OS of 52% in the CheckMate 067
trial, compared to 44% with nivolumab and 26% with ipilimumab [50]. Even after discontinuation, many patients
may continue to derive benefit from combination
nivolumab plus ipilimumab, with similar outcomes for
patients who discontinued treatment because of toxicity
during the induction phase and those who did not [50,
51]. The effect of the combination has also been explored
using a novel endpoint of treatment-free survival (TFS),
defined as the area between Kaplan–Meier curves for
time to immune checkpoint inhibitor protocol therapy
cessation and time to subsequent systemic therapy initiation or death, partitioned as time with and without toxicity [52]. This revealed a long PFS without toxicity after
treatment cessation for patients who received nivolumab
plus ipilimumab. Given the uncertainty of the benefit
of repeated dosing of nivolumab plus ipilimumab, a deescalation study of dropping ipilimumab after two doses
of nivolumab plus ipilimumab for selected patients is
being investigated (NCT03122522).
In another trial, two different combination dose regimens were assessed and showed a significantly lower
incidence of treatment-related grade 3–5 adverse events
with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg compared with the approved doses of nivolumab 1 mg/kg
plus ipilimumab 3 mg/kg [53]. No difference in PFS or
OS was observed between groups, although the study
was not powered to determine whether there was an efficacy difference between these two arms.
Nivolumab plus ipilimumab is also very effective in
melanoma patients with brain metastases, with durable
intracranial responses achieved by 51% of patients with
asymptomatic brain metastases with no prior local brain
therapy [54]. Two-year intracranial PFS was 49% and
2-year OS was 63%. The combination may also have a
role as adjuvant therapy in patients with surgically resectable or completely irradiated stage IV disease. In the
phase II IMMUNED trial in stage IV melanoma patients
with resected or completely irradiated melanoma, adjuvant therapy with nivolumab alone or in combination
with ipilimumab resulted in improved RFS compared
placebo [55]. The rate of grade 3–4 treatment-related
adverse event was higher than reported in the CheckMate 067 trial in patients with metastatic disease, but
no treatment-related deaths had occurred. However, the
combination of nivolumab plus ipilimumab may not be
better than nivolumab monotherapy as adjuvant therapy
for stage III resectable disease (https://news.bms.com/

Responses to immunotherapy preferentially occur in
tumors with a pre-existing antitumor T-cell response
that can be measured by expression of DC and CD8+
T cell-associated genes. The tumor subset with this signature has been described as the T cell-inflamed phenotype. Understanding mechanisms of resistance in
non-inflamed tumors will help address treatment failure
and increase the proportion of patients responding to
immunotherapy.
Intrinsic β-catenin signaling contributes to a lack of
T-cell infiltration in melanoma. β-catenin represses
CCL4, leading to lack of Batf3+ DC recruitment, failed T
cell priming, and lack of response to checkpoint blockade.
There is an inverse correlation between WNT/β-catenin
and T cell-inflamed signature using transcriptional analysis across tumor types [56]. Gene expression signatures
associate with resistance to immune-checkpoint inhibition and mutations associated with T cell-inflamed or
non-T cell-inflamed phenotypes have been clinically
validated. For example, one gene signature, the Tumor
Inflammation Signature (TIS), has been developed as a
clinical-grade assay that provides both quantitative and
qualitative information about the immune environment
within a tumor, reporting on the presence of an immune
infiltrate as well as the functional status of T cells. The
TIS, developed on the NanoString n
Counter® gene
expression system (NanoString Technologies, Inc., Seattle, WA, USA), is an 18-gene signature that measures the
status of adaptive immune response within the tumor.
The TIS contains IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance.
Tumor mutation load or tumor mutation burden
(TMB), measured by comprehensive genomic profiling,
is an important emerging biomarker that shows promise
in its ability to predict the response to immune checkpoint inhibitors. TMB is a measure of the number of
mutations within a tumor genome, defined as the total
number of mutations per coding regions. There is large
variability in TMB within tumor types, ranging from just
a few to thousands of mutations. A high TMB load has
been shown to be associated with better response rates to
checkpoint inhibitors in melanoma, NSCLC, and urothelial carcinoma. Limited responses to anti-PD-1 and
anti-PD-L1 agents are associated with tumor types exhibiting low TMB such as colorectal, ovarian, and prostate
tumors.
Targeting of these mutations or pathways may present
rational immunotherapy combination approaches to
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overcome non-T cell-inflamed tumors or augment immunotherapy in T cell-inflamed tumors and multiple clinical trials are being planned and initiated. For example,
mutations in the isocitrate dehydrogenase (IDH)-1 and
IDH2 genes may facilitate escape from immune surveillance in a subset of malignant gliomas. Reduced expression of CTLA genes and IFN-γ-inducible chemokines
has been shown in IDH-mutated tumors. Treatment with
IDH-C35, a selective mutant IDH-1 inhibitor, restored
chemokine expression, promoted T-cell infiltration, and
increased the efficacy of therapeutic peptide vaccination
against IDH-mutated gliomas in mice [57]. The combination of an IDH1 inhibitor (ivosidenib) plus nivolumab is
now being investigated in a phase II study in patients with
IDH1-mutant advanced solid tumors. Novel clinicalgrade biomarkers are needed to guide the choice of the
immunotherapy agents and combinations to obtain the
maximal likelihood of patient benefit. Translational endpoints include changes in IFN-associated gene expression, epigenetic and metabolomics changes in tumor and
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tumor infiltrating and peripheral blood immune cells and
ctDNA.
Novel circulating biomarkers in melanoma

Predictive biomarkers are needed to help optimally select
patients for adjuvant therapy or treatment of metastatic
disease, to monitor response and recurrence, to better
understand mechanisms of resistance, and to identify
patients at risk of severe toxicity. Biomarkers study can
be used to help develop next generation immunotherapy
agents and combinations treatments for melanoma. In
biomarker enrichment (Fig. 3a), tissue or blood assays
can be used to identify immuno-responsive patients (e.g.
based on PD-L1 status) and non-responsive patients,
who may be enrolled into trials based on biomarker status. Biomarker-directed escalation (Fig. 3b) involves performing assays after initiation of immunotherapy in order
to identify which patients are responsive and should continue therapy and which do not respond and may need
therapy escalated.

Fig. 3 Biomarker enrichment and biomarker-driven escalation. a Biomarker enrichment (current strategy—PD-L1 in NSCLC). b Biomarker-directed
escalation
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Whole plasma and exosome proteomic profiling may
be used to develop a predictive model of immunotherapy response and toxicity, and to obtain insight into the
mechanisms underlying immunotherapy resistance. In
a cohort of 150 melanoma patients receiving anti-PD-1
antibodies whole plasma was analyzed at baseline, and
on-treatment at 6-week and 6-month timepoints [58].
Proteomic analysis in plasma was performed using a
multiplex proximity extension-based assay that enabled simultaneous detection of more than 1000 proteins
including cytokines, chemokines and growth factors.
Patients who responded to immunotherapy vs those
who did not respond had differentially expressed proteins at baseline, including interleukin (IL) 33 receptor
(ST2), IL-6, CCL13 and stem cell factor (SCF) that were
predictive of OS and progression-free survival (PFS).
Whereas high baseline and on-treatment levels of IL-6
have been associated with worse survival in clinical trials
of nivolumab alone or in combination with ipilimumab
[31, 59]. Considering the biomarker-directed escalation,
70 differentially expressed cytokines and chemokines
were identified between baseline and on-treatment
time-points, the majority of which were reflective of
immune activation. In addition, many more differentially
expressed proteins were identified between responders
and non-responders at 6 weeks than at baseline. Several
6-week differentially expressed proteins were predictive
of survival (e.g. Inducible T Cell Costimulatory Ligand
(ICOSLG), IL-8 and MIA). However, it is too early to
consider using these biomarkers in escalation trials and
further validation is ongoing.

Conclusions
Recent insights into genetic and phenotypic characterization of specimens from patients with melanoma have
initiated a new era of rapidly evolving treatments. The
use of novel immunotherapies, especially immune checkpoint inhibitors including CTLA-4, PD-1 and others, as
well as targeted BRAF and MEK inhibitors have significantly improved outcomes for many patients with metastatic melanoma. However, despite these improvements,
most patients still either fail to respond or will relapse
over time. There is a need to increase the ratio of patients
who benefit from the major advances in therapy vs those
who did not benefit. Better understanding of the TME
and host immune response may lead to development of
biomarkers that help identify patients for the best treatment option, as well as new treatments and new combination strategies. Increased use of these new systemic
treatments in the neoadjuvant and adjuvant settings may
also help improve long-term outcomes for patients.
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